Investigating how opioid treatment affects immune health in HIV-infected patients
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment
This study is looking at how different opioid treatments, like methadone, affect the immune system in people with HIV who are also dealing with opioid use disorder and starting medication-assisted treatment, with the goal of finding better ways to support their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10654008 on NIH RePORTER |
What this research studies
This research examines the effects of opioid receptor engagement on immune system function in HIV-infected individuals who are receiving antiretroviral therapy (ART). It focuses on patients with opioid use disorder who are starting medication-assisted treatment, specifically looking at how different types of opioid treatments (like methadone) influence immune activation and microbial translocation. By analyzing the relationship between opioid treatment and immune health, the study aims to provide insights that could improve treatment strategies for this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are HIV-infected individuals who are also diagnosed with opioid use disorder and are initiating medication-assisted treatment.
Not a fit: Patients who are not HIV-infected or do not have opioid use disorder may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols for HIV-infected patients with opioid use disorder, enhancing their immune health and overall well-being.
How similar studies have performed: Previous research has indicated that opioid treatment can significantly impact immune function in HIV-infected populations, suggesting that this study's approach is built on established findings.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Montaner, Luis J — Wistar Institute
- Study coordinator: Montaner, Luis J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.